Cellulase

Cellulase: A Comprehensive Reference

1. Identity and Chemical Classification

Nomenclature and Enzyme Commission Classification

Cellulase (EC 3.2.1.4; systematic name 4-β-D-glucan 4-glucanohydrolase) is any of several enzymes produced chiefly by fungi, bacteria, and protozoans that catalyze cellulolysis, the decomposition of cellulose and of some related polysaccharides, including endohydrolysis of (1→4)-β-D-glucosidic linkages in cellulose, lichenin, and cereal β-D-glucan. The term also refers to any naturally occurring mixture or complex of various such enzymes that act serially or synergistically to decompose cellulosic material.

Cellulase catalyzes the hydrolysis of cellulose. It is not a single enzyme; rather, it is a group of enzymes mainly composed of endoglucanases and exoglucanases, including cellobiohydrolases and β-glucosidases. Together, these three classes form a functionally synergistic multi-component system. All cellulases cleave β-1,4-glucosidic bonds, yet they display a variety of topologies ranging from all β-sheet proteins to β/α-barrels to all α-helical proteins.

According to the Carbohydrate-Active Enzymes (CAZy) database, glycoside hydrolases, including cellulases, have been classified into 115 families based on amino acid sequence similarities and crystal structures. Cellulase genes are found in 13 different families, and 3D structures of more than 50 cellulases have been determined.

The Three Principal Component Classes

• Endoglucanases (endo-1,4-β-D-glucanases; EG; EC 3.2.1.4): These enzymes cleave internal glycosidic bonds at random along the cellulose chain, creating new chain ends and rapidly reducing the degree of polymerization.
• Cellobiohydrolases (exoglucanases; CBH; EC 3.2.1.91): These enzymes act processively from the reducing or non-reducing ends of the cellulose chain, releasing cellobiose (a glucose dimer) as the primary product.
• β-Glucosidases (BG; EC 3.2.1.21): These enzymes hydrolyze cellobiose and short cello-oligosaccharides into individual glucose units, completing the saccharification cascade.

In 1950, Reese et al. proposed the C1–Cx hypothesis, which suggests that different enzymes must work together to thoroughly hydrolyze cellulose into glucose. The synergistic effect is generally understood as the C1 enzyme first attacking the amorphous region of cellulose to form new free ends required for Cx, and then the Cx enzyme cleaving fibrous disaccharide units from the reducing or non-reducing end of the polysaccharide chain. Finally, β-glucosidase hydrolyzes the fibrous disaccharide into two glucose units.

The cellulase system is characterized by its synergistic nature; research has shown that the efficiency of cellulose degradation is significantly higher when all three enzyme types work together compared to the sum of their individual activities. This synergy occurs because each enzyme type addresses different aspects of the cellulose structure: endoglucanases create new chain ends for exoglucanases to attack, while β-glucosidases prevent product inhibition by removing cellobiose. Many cellulases also contain carbohydrate-binding modules that help them adhere to the cellulose surface, further increasing their efficiency.

2. Natural Sources and Biological Distribution

Microbial Producers

Fungi, bacteria, and actinomycetes are recorded to be efficient cellulase enzyme producers in the natural environment. Cellulase enzymes are produced primarily by fungi, bacteria, and protozoans, playing an essential role in recycling plant biomass in natural ecosystems.

In nature, aerobic and anaerobic thermophilic fungi — including Trichoderma reesei, Orpinomyces sp., Humicola insolens, Penicillium decumbens, and Neosartorya fischeri — and bacteria such as Clostridium thermocellum, Clostridium cellulovorans, Ruminococcus flavefaciens, Thermotoga petrophila, Bacillus amyloliquefaciens, Bacillus subtilis, and Lachnoclostridium phytofermentans produce cellulolytic enzymes.

The most prolific cellulase producers are filamentous fungi, particularly species of Trichoderma and Aspergillus. Among these, Trichoderma reesei stands out as one of the most extensively studied and commercially important cellulase producers. Bacterial sources include species from genera such as Cellulomonas, Clostridium, and Bacillus.

The cellulases commonly used in production come from fungi, with typical genera including Trichoderma, Aspergillus, and Penicillium. Fungi and bacteria are most often used in the production of these enzymes because of traits such as considerable yield and cost reduction. Historically, the principal producers of cellulases have been natural strains of fungi, and their productivity has been enhanced through selection and/or mutagenesis methods.

Animal Kingdom

In many herbivorous animals such as ruminants like cattle and sheep and hindgut fermenters like horses, cellulases are produced by symbiotic bacteria. Endogenous cellulases are produced by a few types of animals, such as some termites, snails, and earthworms. Humans do not produce endogenous cellulases.

Cellulose as the Target Substrate

Humans, like all mammals, depend on the gut microbiome for digestion of cellulose, the main component of plant fiber. When people eat plants, they ingest plant cells, fibrous cell walls, and the cellulose within them. Since humans are not able to produce cellulase, these fibers are partially digested by the flora of the large intestine through fermentation. However, this mechanism breaks down only some plant fibers, and others are eliminated from the body.

3. History of Discovery and Commercial Development

Discovery of Trichoderma reesei

More than 70 years ago, the filamentous ascomycete Trichoderma reesei was isolated on the Solomon Islands due to its ability to degrade and thrive on cellulose-containing fabrics. The T. reesei isolate QM6a was originally isolated from the Solomon Islands during World War II because of its degradation of canvas and garments of the US Army. All strains currently used in biotechnology and basic research were derived from this isolate. The isolation of Trichoderma reesei in the 1940s marked the beginning of cellulase research, after which fungal cellulases have been extensively studied to understand the mechanisms of cellulose degradation.

The discovery of the filamentous mesophilic ascomycete Trichoderma reesei (then Trichoderma viride) for its potential to produce extracellular cellulases took place just over 70 years ago. Initially the destructive potential of the original Trichoderma sp. isolated from rotting US Army equipment on the Solomon Islands during World War II was seen as rather problematic. Subsequent scientific investigation transformed this destructive trait into the basis of a major biotechnological industry.

Many strains of T. reesei have been developed since its discovery, with heavy emphasis on increasing cellulase production. Improvement programs originally consisted of classical (ionizing-radiation-based and chemical-based) mutagenesis, which led to strains capable of producing 20 times as much cellulase as the original QM6a strain. Some of the highest performing industrial strains produce up to 100 grams of cellulases per litre.

Traditional and Pre-Scientific Context

It is important to note that cellulase as an isolated enzyme has no traditional medicinal history per se. The concept of cellulase as a defined biochemical entity emerged from 20th-century laboratory science. The most ancient biotechnological practices involving fungi for the production of beer, wine, and cheese might date back several millennia, to the very beginning of literate civilization itself. However, in these ancient fermentation traditions, the cellulose-degrading capacity of microorganisms was harnessed empirically rather than understood or intentionally directed at isolating cellulolytic enzyme activity. The deliberate production and use of purified or semi-purified cellulase preparations as dietary supplements is an entirely modern development dating to the latter half of the 20th century and expanding particularly through the 1990s and 2000s, coinciding with the growth of the broader digestive enzyme supplement market.

4. Regulatory and Commercial Forms

Regulatory Status

GRAS notifications have been submitted and accepted by the FDA with "No questions" letters for the use of cellulases (GRASP petition 9G0260, GRN 584, 479, 292, and 195) from a variety of production organisms. All the GRAS notifications mentioned included sufficient toxicological testing data that showed no evidence of toxicological concern.

DigeZyme® is a combination of five digestive enzymes — α-amylase, protease, cellulase, lactase, and lipase — that help break down carbohydrates, complex proteins, cellulosic fibers, lactose, and fats. The product is present in the market as a dietary ingredient under the trade name DigeZyme® and has self-affirmed Generally Recognized As Safe (GRAS) status in the United States.

Common Commercial Forms

In the US market, cellulase appears mainly in digestive enzyme blends and specialty formulations — including powders, capsules, and enteric-coated preparations — intended to aid the breakdown of insoluble plant fiber, reduce meal-related bloating, and improve the extractability of phytochemicals in manufacturing.

The most common supplemental form is fungal-derived cellulase from Aspergillus niger or Trichoderma reesei. These enzymes are typically acid-stable enough to function in the stomach's acidic environment and are standardized by activity units according to the Food Chemicals Codex (e.g., CU, EGU, or FPU).

Related terms appearing on dietary supplement labels include: Cellulase, Cellulase blend, Cellulase complex, Cellulase enzyme, Cellulase enzymes, Cellulase extract, Cellulase FCC, Cellulase fungal, Cellulase I, Cellulase II, Cellulase I/II, Cellulase powder, Cellulase raw, Fungal cellulase, Plant cellulose enzyme, and Trichoderma sp. This reflects the commercial diversity of formulations available in the supplement marketplace.

Multi-enzymatic complexes often contain fungal cellulase from Aspergillus oryzae, Rhizopus oryzae, or Trichoderma longibrachiatum, obtained from fungal fermentation.

5. Key Constituents and Mechanisms of Action

Biochemical Mechanism in the Gastrointestinal Lumen

Cellulase catalyzes hydrolysis of β-1,4 glycosidic bonds in cellulose, reducing particulate fiber size and producing oligosaccharides and cellobiose, which may be further metabolized by colonic microbiota or by β-glucosidase to glucose. Cellulases break down the cellulose molecule into monosaccharides such as β-glucose, or shorter polysaccharides and oligosaccharides.

Approximately 0% of human digestive enzymes can break β-1,4 linkages in cellulose — exogenous cellulase supplements supply enzymatic activity that targets this otherwise indigestible plant polymer. Cellulase is a multi-component enzyme complex (endo-1,4-β-glucanases, cellobiohydrolases, β-glucosidases) produced by fungi and bacteria and commercialized for industrial and supplemental uses.

Degradation of Intact Plant Cell Walls

The cellulase enzyme is important because it degrades the primary plant cell wall, which, if passed to the colon as intact plant cells, can be attacked by putrefactive bacteria such as C. perfringens, which ferment the contents of the plant cell, causing gastric distress. The presence of the cellulase and hemicellulase enzymes in enzyme food supplement compositions degrades cellulosic and hemicellulosic constituents contained in ingested food, attaining an enhanced quantity of reducing sugars through oligosaccharide conversion, thereby further alleviating gastrointestinal distress.

Synergy with Hemicellulase

Hemicellulase is important because it breaks the structure of xylans and related compounds, which are usually associated with cellulose and lignin in leguminous foods. This enzymatic activity helps to free the cellulose for hydrolysis by cellulase. Consequently, cellulase is frequently formulated alongside hemicellulase, pectinase, and other carbohydrases to exploit this complementary activity.

Stability in the Gastrointestinal Environment

Fungal-derived digestive enzyme preparations, including cellulase, appear to be stable in the gastrointestinal environment, exerting beneficial functions and attenuating symptoms of functional dyspepsia. While some digestive enzymes experience stability issues with oral supplementation, certain enzymes from plants and microbes are known to be stable under a broad pH and temperature range, making them capable of acting throughout the human gastrointestinal tract.

Biofilm Disruption: In Vitro Evidence

Cellulase enzymes may aid in the mediation of biofilm formation from cellulose produced by many types of pathogens, breaking down the polysaccharides of microbial biofilms. In vitro studies show that cellulase enzymes can stop the growth and increase the breakdown of biofilms produced by the bacterium Pseudomonas. This represents an area of preclinical interest, though it has not been confirmed in human clinical studies.

6. Scientific Evidence by Area of Use

6.1 Digestive Support and Functional Dyspepsia

Recent literature emphasizes enzyme engineering, thermostability, acid tolerance, and application to biofuels and feed — high-quality human clinical trials of cellulase supplements remain limited. Despite this, cellulase is a component of several multi-enzyme preparations that have been assessed in human trials.

DigeZyme® (multi-enzyme blend including cellulase) — Randomized Controlled Trial: In recent years, several well-designed clinical studies have shown that pancreatic or digestive enzyme supplements could be promising alternative approaches in managing functional dyspepsia (FD) syndrome. Post-marketing surveillance studies of multi-enzyme formulations to evaluate the efficacy and tolerability revealed that treatment was able to decrease the frequency and severity of various dyspeptic symptoms in FD patients.

Researchers divided 40 subjects with functional dyspepsia into two groups that took three capsules per day of either DigeZyme or a placebo for 60 days. The enzymes in the DigeZyme complex are of bacterial and fungal origin and produced through a fermentation process; specifically, the cellulase component is sourced from Trichoderma longibrachiatum. Results showed that supplementation with DigeZyme had a significantly greater effect on efficacy values compared to placebo.

Larger multi-center RCT: A randomized, placebo-controlled, double-blind clinical trial assessed the effectiveness and tolerability of a multi-enzyme blend obtained from fungal fermentation. Enrolled subjects (n = 120, male: 63, female: 57), aged 18–59 years, were randomized (allocation ratio 1:1) to receive either 2 capsules per day of the food supplement (containing 200 mg of the multi-enzyme blend per capsule) or placebo, for 2 months.

In vitro digestibility study: The effect of a digestive enzyme supplement containing, among other enzymes, cellulase at 1000 CMC/g on complex food digestion was assessed using an INFOGEST simulated static digestion model and a modified semi-dynamic digestion model. The progress of digestion was monitored in terms of reducing sugars, free sugar profile, degree of hydrolysis, free amino acids, peptide pattern, and free fatty acids. This study is an in vitro model only and does not constitute clinical evidence.

Multi-enzyme preparation for IBS-like symptoms: One combination product contained a vegetal analogue of pancreatin with acid-stable protease (4375 USP units), lipase (375 USP units), α-amylase (2614 USP units), as well as amyloglucosidase, cellulase, hemicellulase, and lactase, which clinically seemed to be interchangeable with the original Viokase for the treatment of IBS-D. There were 86 patients with follow-up data, of whom 71 (82.5%) reported an improvement or elimination of their symptoms.

Evidence assessment: A critical limitation across all of these studies is that cellulase was always one component of a multi-enzyme blend, making it impossible to attribute observed effects to cellulase specifically. The clinical evidence specific to cellulase is limited, and benefits are often inferred from mechanistic data or multi-enzyme studies, so expectations should remain measured. High-quality randomized controlled trials assessing orally administered cellulase supplements for human digestive outcomes are sparse.

6.2 Bloating and Gas Reduction

When combined with hemicellulase, pectinase, and alpha-galactosidase, cellulase may contribute to broader breakdown of plant fibers. Alpha-galactosidase has stronger human evidence for reducing gas from legumes; cellulase's role in the multi-enzyme mix is supportive, with moderate-to-mixed evidence for the blend but limited evidence for cellulase alone.

Enzyme food supplement compositions containing cellulase are of value to individuals who have suffered gastrointestinal distress caused by ingesting foods containing the oligosaccharides raffinose, stachyose, and verbascose. These compounds are found primarily in legumes and cruciferous vegetables.

Evidence assessment: Evidence for cellulase-specific benefits in bloating reduction is largely theoretical or derived from multi-enzyme blend studies. No single-ingredient human RCT on cellulase and gas/bloating was identified in the peer-reviewed literature.

6.3 Nutrient Extractability and Absorption

One study of nursing home patients taking a multi-enzyme formula containing cellulase found that they favorably increased markers of protein absorption. This indicates an improvement in digestion of a nutritional formula also given to the study participants, which would lead to an overall better nutritional status. Other tests also indicated an improvement in immune function for the patients. When the enzyme supplement was withdrawn, the positive benefits ended. However, this was a multi-enzyme formula administered to an institutionalized population, limiting generalizability and the ability to attribute effects specifically to cellulase.

Cellulase enzymes can eliminate antinutritional factors present in feed, degrade certain feed constituents to improve nutritional value, and work synergistically with supplementary digestive enzymes such as proteases, amylases, and glucanases. While this evidence base is primarily from animal nutrition research, it provides the mechanistic rationale for human supplementation hypotheses.

6.4 Gut Microbiota Modulation

Evidence for cellulose fermentation in the human gut is scarce. Ruminococcal species in the gut microbiota of human populations have been shown to assemble functional multienzymatic cellulosome structures capable of degrading plant cell wall polysaccharides. One of these species, which is strongly associated with humans, likely originated in the ruminant gut and was subsequently transferred to the human gut, potentially during domestication.

These cellulose-degrading species are abundant and widespread among ancient humans, hunter-gatherers, and rural populations but are rare in populations from industrialized societies, indicating potential disappearance in response to a westernized lifestyle. Whether supplemental exogenous cellulase can compensate for this deficit has not been established in clinical research.

Since the early 1980s, studies have shown that despite its limited fermentation to short-chain fatty acids (SCFAs), cellulose is able to substantially modify the colonic microbiota, classifying cellulose as a potential prebiotic. The metabolism of cellulose in humans has long been subject of scientific interest. However, this line of research pertains to dietary cellulose intake rather than exogenous cellulase supplementation per se, and the two should not be conflated.

Evidence assessment: Evidence for cellulase supplementation specifically modulating human gut microbiota is absent. Research on cellulose and microbial diversity has been conducted primarily in animal models, and translating these findings directly to exogenous cellulase enzyme supplementation in humans remains speculative.

6.5 Animal Studies: Nutrient Digestibility

A study examined the effect of supplementing exogenous cellulase on nutrient and energy utilization in twelve desexed Boer crossbred goats in a replicated 3×3 Latin square design. Dietary treatments were a basal diet (control, no cellulase), the basal diet plus 2 g unitary cellulase/kg of total mixed ration dry matter (DM), and the basal diet plus 2 g compound cellulase/kg of total mixed ration DM. Results showed that cellulase addition had no effect (p>0.05) on nutrient digestibility. This animal study underscores that the benefit of exogenous cellulase supplementation is not guaranteed even in non-human subjects, and results may depend on the dietary matrix, dose, and enzyme preparation.

7. Body Systems and Health Areas

Gastrointestinal System

Cellulase as a supplement is primarily directed at the gastrointestinal system. Its activity occurs within the intestinal lumen, where it can reduce the structural integrity of plant cell walls before they reach the large intestine. The cellulase enzyme degrades the primary plant cell wall, which if passed to the colon as intact plant cells can be attacked by putrefactive bacteria such as C. perfringens, which ferment the contents of the plant cell, causing gastric distress.

Gut Microbiome

Dietary fiber is beneficial to gut microbiome stability and richness and has important implications for human health. Fermentation of dietary fiber in the human gut regulates digestive transit, prevents obesity and diabetes, and reduces cardiovascular diseases and cancer. Microbial activity transforms indigestible glycans into short-chain fatty acids which supply energy to the host and have multiple systemic effects. Exogenous cellulase theoretically participates in this process by expanding the pool of fermentable carbohydrates available to the microbiome, though this mechanism has not been specifically validated in human studies of cellulase supplementation.

Immune Function

Fiber supplementation, by promoting the growth of bacteria that are considered pro-health influences, influences the immune system and thus modulates the inflammatory response. Because cellulase acts on dietary fiber, theoretical downstream immune effects have been hypothesized, but direct immunomodulatory evidence from cellulase supplementation trials in humans is absent.

8. Dosage Forms and Dosages Reported in Studies

Units of Measurement

There is no NIH/ODS or FDA-endorsed daily intake for cellulase; commercial dosages vary and activity units (FPU/CU) are the preferred reference metric. These enzymes are typically standardized by activity units according to the Food Chemicals Codex (e.g., CU, EGU, or FPU). CU stands for Cellulase Units; FPU for Filter Paper Units; EGU for Endo-Glucanase Units. Activity units rather than weight alone are the scientifically meaningful measure of enzyme dose.

Dosages Reported in Research and Commercial Contexts

• In a randomized, double-blind, placebo-controlled trial for functional dyspepsia, subjects received 2 capsules per day of a food supplement containing 200 mg of the multi-enzyme blend per capsule for 2 months. (Cellulase was one component of this blend.)
• In a 40-subject functional dyspepsia study using DigeZyme (containing cellulase from Trichoderma longibrachiatum), participants took three capsules per day for 60 days.
• An in vitro study employed a digestive enzyme supplement (DigeSEB Super) containing cellulase at 1000 CMC/g alongside amylase (20,000 SKBU/g), protease (13,000 PC/g), lipase (5 LU/g), lactase (1000 ALU/g), and hemicellulase (15,000 XU/g).
• An enzyme preparation containing 24 mg enzyme extract of Aspergillus oryzae (providing cellulase, protease, and amylase) and 220 mg pancreatin, given post-meal (2 tablets) three times a day, was assessed in patients with chronic digestive diseases.
• One patent-based formulation specifies that dosage should not exceed 110,000 CU per day and should be taken with food/meals.
• Common consumer formulations typically contain between 50–500 mg per capsule, but activity can vary significantly — prioritizing FPU/CU labeling is recommended.

In an animal nutrition trial, dietary treatments included the basal diet plus 2 g unitary cellulase/kg of ration dry matter. The enzymes used were commercial preparations of fungal extracts; the unitary cellulase additive contained 10,000 IU/g of cellulase (endoglucanase, EC 3.2.1.4) activity. These animal dosages are not applicable to human supplementation but illustrate that enzyme activity expression varies by preparation.

9. Safety Considerations and Interactions

Regulatory Safety Status

Multiple GRAS notifications have been submitted and accepted by FDA with "No questions" responses for the use of cellulases from a variety of production organisms. All GRAS notifications included sufficient toxicological testing data which showed no evidence of toxicological concern.

The EFSA Panel considered that, under the intended conditions of use, the risk of allergic sensitization and elicitation reactions by dietary exposure can be excluded in distilled alcohol production and is considered to be low when the enzyme is used in starch processing and brewing processes. Based on the data provided, the Panel concluded that this food enzyme does not give rise to safety concerns under the intended conditions of use.

Toxicology Data

In an EFSA evaluation of a cellulase from Penicillium funiculosum, genotoxicity tests did not raise a safety concern. Systemic toxicity was assessed by means of a repeated dose 90-day oral toxicity study in rats. The Panel identified a no observed adverse effect level (NOAEL) of 84 mg TOS/kg body weight per day, the highest dose tested, which when compared with the estimated dietary exposure, resulted in a margin of exposure of at least 200.

In a separate EFSA evaluation of cellulase from Trichoderma reesei (strain DP-Nzc36), the Panel identified a NOAEL of 97.6 mg TOS/kg body weight per day, the highest dose tested.

In a safety evaluation of alkaline cellulase, general toxicity by a variety of routes was low; there was no evidence of reproductive toxicity. There was evidence of mild skin irritation and some eye conjunctival reddening. There was no evidence of skin sensitization, mutagenic potential, ecotoxicity, or notable pathogenicity. When these results are considered along with levels of human exposure and previously published data, it appears that alkaline cellulase is safe for consumers in the given applications.

Occupational Allergy: A Documented Risk

Enzymes have long been known to be respiratory allergens, but relatively few cases of skin allergy have been reported. Four patients have been described who developed occupational allergic respiratory symptoms — three with bronchial asthma and one with allergic rhinitis — caused by cellulase and/or xylanase enzymes. Each patient also had urticarial symptoms after skin contact with these enzymes. In addition, one of the patients had allergic contact dermatitis from cellulase.

Two patients have been reported with asthma induced by occupational exposure to cellulase powder derived from Aspergillus niger. A type I hypersensitivity to this enzyme was demonstrated by means of skin test reactivity, positive passive transfer test, positive reverse enzyme immunoassay for specific IgE, and immediate bronchial provocation test response to cellulase dust. Skin tests with an A. niger extract were positive, and cross-reactivity between cellulase dust and an entire A. niger extract was also demonstrated.

Inhalation of cellulase can induce IgE-mediated bronchoconstrictions in employees working in the textile industry. This risk is relevant to workers handling cellulase in industrial or manufacturing settings. The risk via oral supplementation (i.e., ingesting capsules) is categorically different from inhalational occupational exposure.

No information is available on oral and respiratory sensitization or elicitation reactions from this specific cellulase preparation. Respiratory allergy following occupational inhalation of cellulase has been reported. However, some studies have shown that adults with occupational asthma to an enzyme used in food can commonly ingest the corresponding allergen without acquiring clinical symptoms of food allergy. Information on adverse reactions upon ingestion of cellulase in individuals sensitized through the respiratory route has not been reported; therefore, it can be concluded that an allergic reaction upon oral ingestion of cellulase in individuals who are respiratory-sensitized to cellulase cannot be excluded, but the likelihood of such a reaction is considered to be low.

Allergenicity Assessment

In a systematic evaluation, the similarity of the amino acid sequence of the food enzyme to those of known allergens was searched and no match was found. The allergenicity of cellulase produced with a genetically modified T. reesei strain was assessed by comparing its amino acid sequence with those of known allergens. Using higher than 35% identity in a sliding window of 80 amino acids as criterion, no match was found.

Interaction with Gut Microbiome: Theoretical Consideration

By catalyzing hydrolysis of β-1,4 glycosidic bonds in cellulose and producing oligosaccharides and cellobiose, exogenous cellulase may alter the substrates available for colonic microbiota fermentation. Whether this alters microbial ecology favorably, unfavorably, or negligibly in healthy individuals has not been studied in clinical trials.

Absence of Known Drug Interactions

Peer-reviewed literature does not document pharmacokinetic drug interactions between orally administered cellulase supplements and pharmaceutical agents. Since cellulase acts locally within the gastrointestinal lumen and is itself a protein subject to proteolytic degradation in the gut, systemic absorption and systemic drug interactions are not an established concern. However, this absence of documented interactions partly reflects the absence of pharmacological studies rather than confirmed safety.

10. Overall Evidence Assessment

Small studies, in vitro experiments, and user reports suggest possible benefits for digestive comfort, but robust clinical trials are scarce. As such, expectations should be cautious and usage personalized.

Few clinical studies had shown significance of enzyme supplements in improving digestion and treating digestive disorders. Where human clinical evidence does exist for digestive enzyme preparations containing cellulase, it consistently involves multi-enzyme formulations. No placebo-controlled, double-blind human trial has isolated cellulase as the sole active ingredient and demonstrated a statistically significant clinical outcome in a peer-reviewed publication identified during this research. The mechanistic basis for cellulase supplementation is well established — humans lack endogenous cellulosic enzyme activity — but this biochemical rationale has not been translated into a robust human clinical evidence base specifically for cellulase.

The strongest evidence for cellulase-containing preparations comes from the multi-enzyme functional dyspepsia trials using DigeZyme® and similar products. These trials demonstrate that the blends are tolerable and associated with symptom improvement, but the specific contribution of the cellulase component within those blends cannot be disaggregated from the combined enzyme effects.

References

• Bischof RH, Ramoni J, Seiboth B. Cellulases and beyond: the first 70 years of the enzyme producer Trichoderma reesei. Microbial Cell Factories, 2016. PMC4902900.
• Wikipedia: Cellulase (EC 3.2.1.4)
• Wikipedia: Trichoderma reesei
• Microbial Cellulases: An Overview and Applications. IntechOpen, 2019.
• Effects of Cellulase Supplementation on Nutrient Digestibility, Energy Utilization and Methane Emission by Boer Crossbred Goats. PMC4698700.
• Cryptic diversity of cellulose-degrading gut bacteria in industrialized humans. PMC7615765.
• Dietary cellulose induces anti-inflammatory immunity and transcriptional programs via maturation of the intestinal microbiota. PMC7583510.
• Safety evaluation of the food enzyme cellulase from Trichoderma reesei (strain DP-Nzc36). PMC7008798. EFSA Journal 2020.
• Safety evaluation of the food enzyme cellulase from Penicillium funiculosum strain DP-Lzc35. PubMed PMID: 33437320.
• Safety evaluation of the food enzyme cellulase from Trichoderma reesei (strain DP-Nzc36). PubMed PMID: 32626137.
• Allergy from cellulase and xylanase enzymes. PubMed PMID: 1742654.
• Occupational asthma and IgE sensitization to cellulase in a textile industry worker. PubMed PMID: 10071521.
• Occupational asthma caused by cellulase. Losada E et al. J Allergy Clin Immunol. 1986. PubMed PMID: 3958392.
• Safety evaluation of alkaline cellulase. PubMed PMID: 1761259.
• Evaluation of the Safety and Efficacy of a Multienzyme Complex in Patients with Functional Dyspepsia: A Randomized, Double-Blind, Placebo-Controlled Study. PMC6249666.
• Enzyme therapy for functional bowel disease-like post-prandial distress. PMC6910206.
• In vitro simulated study of macronutrient digestion in complex food using digestive enzyme supplement. PMC11066670.
• Efficacy of digestive enzyme supplementation in functional dyspepsia: A monocentric, randomized, double-blind, placebo-controlled, clinical trial. ScienceDirect, 2023.
• FDA GRAS Notice: A Cellulase Enzyme from Trichoderma reesei Produced by Aspergillus niger (Novozymes).
• FDA GRAS Notice GRN 891 Agency Response Letter — Cellulase produced by Trichoderma reesei.
• Cellulase Enzymes: Classification and Applications. Food Safety Institute, 2025.
• Cellulases: key properties, natural sources, and industrial applications. PMC12876952.
• Cellulase II — NIH Office of Dietary Supplements Dietary Supplement Label Database (DSLD).
• Cellulase — an overview. ScienceDirect Topics (Biochemistry, Genetics and Molecular Biology).